The effect of vitamin E on genes involved in implantation in infertile women.

Effect of vitamin E on endometrial thickness and oxidative stress factor and gene expression of IL-6 and vascular endothelial growth factor (VEGF) in the blood of women with implantation problem

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016050920374N5

Enrollment

Registered

2017-01-13

Start date

2016-06-01

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility and implantation problems. Pregnancy with abortive outcome

Interventions

Intervention 1: The intervention group received a dose of 400 IU vitamin E Zahravi purchased from pharmaceutical companies and patients given take a number of the drug every day for three months. Brie

Eligibility

Sex/Gender

Female

Age

25 Years to 36 Years

Inclusion criteria

Inclusion criteria: Women with implantation problem Age range of 25–36 years old

Exclusion criteria

Exclusion criteria: Having an abnormal uterus Having a polycysticovary syndrome Glucose intolerance Thyroid disease Having autoimmune diseases or cancer Smoking The lack of intention to continue cooperationin the study.

Design outcomes

Primary

Measure	Time frame
Endometrial thickness. Timepoint: Beginning of the study and three months later. Method of measurement: By vaginal ultrasound.	—

Secondary

Measure	Time frame
Malondialdehyde. Timepoint: Beginning of the study and three months later. Method of measurement: Spectrophotometry.;Vitamin E. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Follicle-stimulating hormone. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Luteinizing hormone. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Estradiol (. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Progesterone. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Vascular endothelial growth factor. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Oxidized low-density lipoprotein (Ox-LDL). Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Interleukin-1. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Interleukin-6. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Interleukin-8. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Tumor necrosis factor alpha. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.	—

Measure

Time frame

Malondialdehyde. Timepoint: Beginning of the study and three months later. Method of measurement: Spectrophotometry.;Vitamin E. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Follicle-stimulating hormone. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Luteinizing hormone. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Estradiol (. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Progesterone. Timepoint: Beginning of the study and three months later. Method of measurement: ELISA kit.;Vascular endothelial growth factor. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Oxidized low-density lipoprotein (Ox-LDL). Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Interleukin-1. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Interleukin-6. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Interleukin-8. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.;Tumor necrosis factor alpha. Timepoint: Beginning of the study and three months later. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. E. Aghadavood Jolfaee

Kashan University of Medical Sciences

aghadavod@kaums.ac.ir+98 315554021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026